Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The term "Other NaV channel alpha-subunits, extracellular site 3" refers to the neurotoxin receptor site 3 found across the various isoforms of the voltage-gated sodium channel (NaV) family, including NaV1.1 through NaV1.9 (Alexander et al., 2021). These alpha-subunits are large transmembrane proteins that form the ion-conducting pore and are essential for the generation and propagation of action potentials in neurons, cardiomyocytes, and skeletal muscle cells (Catterall, 2012). Extracellular site 3 is specifically located on the S3-S4 loop of domain IV and serves as the binding target for alpha-scorpion toxins and sea anemone toxins (Stevens et al., 2011). Binding at this site impairs the voltage-sensing mechanism of domain IV, which is coupled to the fast inactivation process, thereby slowing channel closure and causing persistent sodium influx (Gordon et al., 1996). This prolonged activation leads to cellular hyperexcitability, which is a hallmark of various channelopathies, including epilepsy, chronic pain syndromes, and cardiac arrhythmias (Catterall, 2012). While site 3 is primarily used as a pharmacological tool to study channel gating, it represents a potential target for developing modulators that can fine-tune excitability in specific tissues (Stevens et al., 2011).
Binding to the extracellular S3-S4 loop of domain IV slows the inactivation of the sodium channel, prolonging the inward sodium current and increasing membrane excitability.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Voltage-gated sodium channel alpha-subunit extracellular site 3 (NaV site 3).